Table 4.
Comparison of molecular subtyping using MP and BP tests (Luminal A for Low Risk MP and Luminal B for High Risk) between NGS Beta Site and IHC according to Prat et al. (n = 124) (A), between NGS Beta Site and IHC according to Maisonneuve et al. (n = 124) (B), between NGS Beta Site and microarray Agendia (n = 124) (C), and between NGS Beta Site and NGS Agendia (n = 114∗) (D). These results show a concordance of 71.8% (89/124) (A), 76.6% (95/124) (B), 89.5% (111/124) (C) and 93.9% (107/114) (D).
| A. |
|||||
|---|---|---|---|---|---|
| MP/BP NGS Beta Site |
|||||
| IHC | Luminal A | Luminal B | HER2 | Basal | Total |
| Luminal A-like | 52 | 18 | 0 | 0 | 70 |
| Luminal B-like, HER2-negative |
10 | 11 | 0 | 1 | 22 |
| Luminal B-like, HER2-positive |
5 | 7 | 5 | 0 | 17 |
| HER2-positive | 0 | 0 | 3 | 0 | 3 |
| Triple negative | 0 | 1 | 0 | 11 | 12 |
| Total | 67 | 37 | 8 | 12 | 124 |
| B. | |||||
| Luminal A-like | 53 | 13 | 0 | 0 | 66 |
| Luminal A-like | 53 | 13 | 0 | 0 | 66 |
| Luminal B-like, HER2-negative |
9 | 16 | 0 | 1 | 26 |
| Luminal B-like, HER2-positive |
5 | 7 | 5 | 0 | 17 |
| HER2-positive | 0 | 0 | 3 | 0 | 3 |
| Triple negative | 0 | 1 | 0 | 11 | 12 |
| Total | 67 | 37 | 8 | 12 | 124 |
| C. | |||||
| Microarray | Luminal A | Luminal B | HER2 | Basal | Total |
| Luminal A | 60 | 4 | 0 | 0 | 64 |
| Luminal B | 7 | 31 | 0 | 0 | 38 |
| HER2 | 0 | 2 | 8 | 0 | 10 |
| Basal | 0 | 0 | 0 | 12 | 12 |
| Total | 67 | 37 | 8 | 12 | 124 |
| D. | |||||
| NGS Agendia | Luminal A | Luminal B | HER2 | Basal | Total |
| Luminal A | 58 | 1 | 0 | 0 | 59 |
| Luminal B | 6 | 31 | 0 | 0 | 37 |
| HER2 | 0 | 0 | 7 | 0 | 7 |
| Basal | 0 | 0 | 0 | 11 | 11 |
| Total | 64 | 32 | 7 | 11 | 114∗ |
∗
For 10 samples, no NGS results were obtained at Agendia.